Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929110 · ClinicalTrials.gov registry record · Phase 3
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,066
- Enrollment target
NCT00929110: Completed Phase 3 study, sponsored by Novartis.
NCT00929110 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,066 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00929110, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,066 participants
- Enrollment target
Study Summary
This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.
Primary Outcome
FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included baseline FEV1 measurement, baseline inhaled corticosteroid use (Yes/No), FEV1 prior to inhalation of short-acting β2 agonist (SABA), and FEV1 45 min post-inhalation of SABA as covariates.
Interventions
- DRUG Tiotropium
- DRUG Glycopyrronium bromide
- DRUG Placebo to glycopyrronium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,066 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
What the finished NCT00929110 record still lists
NCT00929110 is an interventional study that assigns participants to a tested intervention. Its 1,066 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% higher).
The record links to 0 conditions, and to 3 interventions - of which Tiotropium is the first listed.
NCT00929110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00929110 about?
NCT00929110 is a clinical study titled "1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)". This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.
What is the current status of trial NCT00929110?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,066 participants. The study started on 2009-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00929110?
The interventions under investigation include: Tiotropium (DRUG), Glycopyrronium bromide (DRUG), Placebo to glycopyrronium bromide (DRUG).
Who is sponsoring clinical trial NCT00929110?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00929110's enrollment target sits among peer trials
1,066 274th of 2000 higher than 1,727 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia